Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Cancer immunotherapy, also called biologic therapy, which can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body's immune system to attack tumours.
The report details the trend, potential and market size of Cancer Immunotherapies market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Cancer Immunotherapiesmarket, defines the market attractiveness level of Cancer Immunotherapies market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Cancer Immunotherapies industry, describes the types of Cancer Immunotherapies market, the applications of major players and the market size, and deeply analyzes the current situation of the global Cancer Immunotherapies market and the development prospects and opportunities of Cancer Immunotherapies industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Cancer Immunotherapies market in Chapter 13.
By Player:
Roche
Johnson & Johnson
ARMO BioSciences (Eli Lilly)
Amgen
Pfizer
AbbVie
Gilead Sciences
Novartis
Bayer
Merck
Bristol-Myers Squibb
AstraZeneca
By Type:
Monoclonal Antibodies (MABs)
Cancer Vaccines
Immunomodulators
Adoptive Cell transfer
Checkpoint Inhibitors
By End-User:
Breast Cancer
Leukemia
Lymphoma
Melanoma
Colorectal Cancer
Non-Small Cell Lung Cancer
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Cancer Immunotherapies Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Cancer Immunotherapies Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Cancer Immunotherapies Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Cancer Immunotherapies Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Cancer Immunotherapies Market Analysis and Outlook to 2022
-
7.1 Global Cancer Immunotherapies Consumption (2017-2022)
-
7.2 United States Cancer Immunotherapies Consumption (2017-2022)
-
7.3 Europe Cancer Immunotherapies Consumption (2017-2022)
-
7.4 China Cancer Immunotherapies Consumption (2017-2022)
-
7.5 Japan Cancer Immunotherapies Consumption (2017-2022)
-
7.6 India Cancer Immunotherapies Consumption (2017-2022)
-
7.7 South Korea Cancer Immunotherapies Consumption (2017-2022)
8 Region and Country-wise Cancer Immunotherapies Market Analysis and Outlook to 2028
-
8.1 Global Cancer Immunotherapies Consumption Forecast (2022-2028)
-
8.2 United States Cancer Immunotherapies Consumption Forecast (2022-2028)
-
8.3 Europe Cancer Immunotherapies Consumption Forecast (2022-2028)
-
8.4 China Cancer Immunotherapies Consumption Forecast (2022-2028)
-
8.5 Japan Cancer Immunotherapies Consumption Forecast (2022-2028)
-
8.6 India Cancer Immunotherapies Consumption Forecast (2022-2028)
-
8.7 South Korea Cancer Immunotherapies Consumption Forecast (2022-2028)
9 Global Cancer Immunotherapies Market Outlook by Types and Applications to 2022
-
9.1 Global Cancer Immunotherapies Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Monoclonal Antibodies (MABs) Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Cancer Vaccines Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Immunomodulators Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Adoptive Cell transfer Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Checkpoint Inhibitors Consumption and Growth Rate (2017-2022)
-
9.2 Global Cancer Immunotherapies Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Breast Cancer Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Leukemia Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Lymphoma Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Melanoma Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Colorectal Cancer Consumption and Growth Rate (2017-2022)
-
9.2.6 Global Non-Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
10 Global Cancer Immunotherapies Market Outlook by Types and Applications to 2028
-
10.1 Global Cancer Immunotherapies Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Monoclonal Antibodies (MABs) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Cancer Vaccines Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Immunomodulators Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Adoptive Cell transfer Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Checkpoint Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Cancer Immunotherapies Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Leukemia Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Lymphoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Melanoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.5 Global Colorectal Cancer Consumption Forecast and Growth Rate (2022-2028)
-
10.2.6 Global Non-Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
11 Global Cancer Immunotherapies Import and Export Analysis (Top 5 Countries)
-
11.1 Global Cancer Immunotherapies Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Cancer Immunotherapies Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Cancer Immunotherapies Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Cancer Immunotherapies Market Competitive Analysis
-
14.1 Roche
-
14.1.1 Roche Company Details
-
14.1.2 Roche Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Roche Cancer Immunotherapies Product and Service
-
14.2 Johnson & Johnson
-
14.2.1 Johnson & Johnson Company Details
-
14.2.2 Johnson & Johnson Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Johnson & Johnson Cancer Immunotherapies Product and Service
-
14.3 ARMO BioSciences (Eli Lilly)
-
14.3.1 ARMO BioSciences (Eli Lilly) Company Details
-
14.3.2 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product and Service
-
14.4 Amgen
-
14.4.1 Amgen Company Details
-
14.4.2 Amgen Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Amgen Cancer Immunotherapies Product and Service
-
14.5 Pfizer
-
14.5.1 Pfizer Company Details
-
14.5.2 Pfizer Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Pfizer Cancer Immunotherapies Product and Service
-
14.6 AbbVie
-
14.6.1 AbbVie Company Details
-
14.6.2 AbbVie Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 AbbVie Cancer Immunotherapies Product and Service
-
14.7 Gilead Sciences
-
14.7.1 Gilead Sciences Company Details
-
14.7.2 Gilead Sciences Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Gilead Sciences Cancer Immunotherapies Product and Service
-
14.8 Novartis
-
14.8.1 Novartis Company Details
-
14.8.2 Novartis Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Novartis Cancer Immunotherapies Product and Service
-
14.9 Bayer
-
14.9.1 Bayer Company Details
-
14.9.2 Bayer Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Bayer Cancer Immunotherapies Product and Service
-
14.10 Merck
-
14.10.1 Merck Company Details
-
14.10.2 Merck Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Merck Cancer Immunotherapies Product and Service
-
14.11 Bristol-Myers Squibb
-
14.11.1 Bristol-Myers Squibb Company Details
-
14.11.2 Bristol-Myers Squibb Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Bristol-Myers Squibb Cancer Immunotherapies Product and Service
-
14.12 AstraZeneca
-
14.12.1 AstraZeneca Company Details
-
14.12.2 AstraZeneca Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
14.12.3 AstraZeneca Cancer Immunotherapies Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Cancer Immunotherapies
-
Figure Cancer Immunotherapies Picture
-
Table Global Cancer Immunotherapies Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Cancer Immunotherapies Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Cancer Immunotherapies Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Cancer Immunotherapies Consumption by Country (2017-2022)
-
Figure United States Cancer Immunotherapies Consumption and Growth Rate (2017-2022)
-
Table Europe Cancer Immunotherapies Consumption and Growth Rate (2017-2022)
-
Figure China Cancer Immunotherapies Consumption and Growth Rate (2017-2022)
-
Figure Japan Cancer Immunotherapies Consumption and Growth Rate (2017-2022)
-
Figure India Cancer Immunotherapies Consumption and Growth Rate (2017-2022)
-
Figure South Korea Cancer Immunotherapies Consumption and Growth Rate (2017-2022)
-
Figure Global Cancer Immunotherapies Consumption Forecast by Country (2022-2028)
-
Figure United States Cancer Immunotherapies Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Cancer Immunotherapies Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Cancer Immunotherapies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Cancer Immunotherapies Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Cancer Immunotherapies Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Cancer Immunotherapies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Monoclonal Antibodies (MABs) Consumption and Growth Rate (2017-2022)
-
Figure Global Cancer Vaccines Consumption and Growth Rate (2017-2022)
-
Figure Global Immunomodulators Consumption and Growth Rate (2017-2022)
-
Figure Global Adoptive Cell transfer Consumption and Growth Rate (2017-2022)
-
Figure Global Checkpoint Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Leukemia Consumption and Growth Rate (2017-2022)
-
Figure Global Lymphoma Consumption and Growth Rate (2017-2022)
-
Figure Global Melanoma Consumption and Growth Rate (2017-2022)
-
Figure Global Colorectal Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Non-Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Monoclonal Antibodies (MABs) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Cancer Vaccines Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Immunomodulators Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Adoptive Cell transfer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Checkpoint Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Leukemia Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lymphoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Melanoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Colorectal Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Non-Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Cancer Immunotherapies Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Cancer Immunotherapies Export by Region (Top 5 Countries) (2017-2028)
-
Table Roche (Foundation Year, Company Profile and etc.)
-
Table Roche Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Cancer Immunotherapies Product and Service
-
Table Johnson & Johnson (Foundation Year, Company Profile and etc.)
-
Table Johnson & Johnson Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Johnson & Johnson Cancer Immunotherapies Product and Service
-
Table ARMO BioSciences (Eli Lilly) (Foundation Year, Company Profile and etc.)
-
Table ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product and Service
-
Table Amgen (Foundation Year, Company Profile and etc.)
-
Table Amgen Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Cancer Immunotherapies Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Cancer Immunotherapies Product and Service
-
Table AbbVie (Foundation Year, Company Profile and etc.)
-
Table AbbVie Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table AbbVie Cancer Immunotherapies Product and Service
-
Table Gilead Sciences (Foundation Year, Company Profile and etc.)
-
Table Gilead Sciences Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gilead Sciences Cancer Immunotherapies Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Cancer Immunotherapies Product and Service
-
Table Bayer (Foundation Year, Company Profile and etc.)
-
Table Bayer Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Cancer Immunotherapies Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Cancer Immunotherapies Product and Service
-
Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)
-
Table Bristol-Myers Squibb Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Cancer Immunotherapies Product and Service
-
Table AstraZeneca (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca Cancer Immunotherapies Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Cancer Immunotherapies Product and Service
-
